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Abstract 
 
Purpose: The European Academy of Allergy and Clinical Immunology (EAACI) has produced 
Guidelines on Allergen Immunotherapy (AIT). We sought to gauge the preparedness of primary care 
to participate in the delivery of AIT in Europe.  
Methods: We undertook a mixed-methods, situational analysis. This involved a purposeful literature 
search, and two surveys: one to primary care clinicians and the other to a wider group of stakeholders 
across Europe.  
Results: The 10 papers identified all pointed out gaps or deficiencies in allergy care provision in 
primary care. The surveys also highlighted similar concerns, particularly in relation to concerns about 
lack of knowledge, skills, infrastructural weaknesses, reimbursement policies and communication with 
specialists as barriers to evidence-based care. Almost all countries (92%) reported the availability of 
AIT. In spite of that, only 28% and 44% of the countries reported the availability of guidelines for 
primary care physicians and specialists, respectively. Agreed pathways between specialists and 
primary care physicians were reported as existing in 32-48% of countries. Reimbursement appeared 
to be an important barrier as AIT was only fully reimbursed in 32% of countries. Additionally, 44% of 
respondents considered accessibility to AIT and 36% stating patient costs were barriers.  
Conclusions: Successful working with primary care providers is essential to scaling-up AIT provision 
in Europe, but to achieve this the identified barriers must be overcome. Development of primary care 
interpretation of guidelines to aid patient selection, establishment of disease management pathways 
and collaboration with specialist groups are required as a matter of urgency.  
 
Introduction 
The march of allergy proceeds relentlessly with up to a third of the general population and half of 
young people suffering from some manifestation of the disease at some stage in their lives. 
1
  The 
most prevalent of these conditions are atopic eczema/dermatitis, asthma and allergic rhinitis
2-5
.
   
These result in a significant impact at the personal level because of impaired quality of life, a 
significant impact on family  and friends,  on the health care system because of increased medical 
costs and at a societal level because of lost productivity through presenteeism and absenteeism
6,7
. 
Currently, allergy is often not well recognized and is as a result poorly managed
8
. Patients seek 
assistance from various sources, often involving considerable expense and inappropriate treatment
9-
11
.  Primary care professionals (hereafter referred to as PCPs, these including general practitioners, 
nurses and pediatricians, in some countries
12
, are poorly equipped to deal with the management of 
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allergy, particularly the more complex issues associated with AIT, due to deficiencies in 
undergraduate and postgraduate training
13
. Previous surveys have revealed a low level of PCPs’ self-
estimated knowledge or confidence in delivering AIT
12
. To date, there is no care system which 
delivers comprehensive allergy care in a systematic fashion
14
.  
 
In most cases, the management of allergy comprises  allergen avoidance
15
  and symptom alleviation 
by pharmacotherapy. This contrasts with allergen immunotherapy (AIT) which targets the 
immunological basis of the disease. It can be used as complementary to or in some cases as an 
alternative to pharmacotherapy in patients for whom pharmacotherapy is not sufficiently effective or 
for patients who prefer a disease-modifying treatment over chronic, often life-long use of symptom 
relieving drugs
16
. AIT involves the administration of allergen to deviate the immune response from 
immediate hypersensitivity towards tolerance
17
. Typically, either injection (subcutaneous AIT, SCIT), 
sublingual AIT (SLIT) or oral AIT (OIT) are used
18
.   
 
The European Academy of Allergy and Clinical Immunology (EAACI) has embarked on a process of 
formulating comprehensive guidelines for AIT supported by underpinning systematic reviews on the 
effectiveness, cost-effectiveness and safety of AIT for allergic rhinitis
19
, asthma
20,21
,venom allergy
22
, 
food allergy,
 23
 and the prevention of allergy and allergic disorders
24
. The EAACI Guidelines on AIT 
should help to identify patients who are most likely to benefit from this potentially disease-modifying 
treatment while also highlighting the current gaps in knowledge and service provision.  
 
For comprehensive AIT services to be implemented, a system-wide approach is needed, commencing 
and ultimately culminating in primary care. This requires an understanding of primary care
25
 taking 
into account the significant regional and national variation in configuration of health services across 
Europe.
26
  AIT needs to be seen in the wider context of overall provision of care for allergic patients, 
which itself needs to be contextualized within overall healthcare provision.  
 
We have performed a mixed-method, situational analysis of current provision of AIT, comprising of a 
literature review and surveys, in primary care across Europe. This was done as part of the EAACI AIT 
Guidelines initiative and aimed to develop a summary of the current deficits in the service delivery of 
allergy care and AIT across the whole health system. We collected survey data from: (i) GPs; and (ii) 
allergy stakeholders, including patient and specialist organizations. We focused on asthma, allergic 
rhinitis and venom allergy; we excluded AIT for food allergy and allergy prevention as these are 
developing areas. Our aim was to summarize the different perspectives on the current capabilities of 
primary care in the provision of allergy management, in particular AIT. It will build on our previous 
EAACI position paper.
27
 and work performed in the UK.
28
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Methods 
We developed a mixed-methods approach to assess the current capabilities of AIT provision in 
primary care, and used our findings to draw up a list of recommendations.  
 
Literature search 
To inform our paper, we (DR, EA) performed a focused PubMed literature search (see Online 
supplement for search strategy ). This was supplemented by a (UK) Royal College of General 
Practitioners Discovery and Medline search. The abstracts were assessed by DR and EA. Papers not 
written in English and irrelevant papers were rejected. The remaining papers were read in full. Due to 
the diversity of papers with few recurring themes, a narrative description of the literature search was 
undertaken. 
 
Situational analysis 
We undertook a situational assessment using an online questionnaire (see Online repository) to 
understand the perspectives of stakeholders: (1) General Practitioners (GPs), and (2) stakeholders 
(specialist allergy societies and patient organizations) in different European countries. We developed 
a draft survey, which was piloted and, where necessary, revised. There were 12 questions for GPs 
and 10 questions for stakeholders (see Online supplement). A combination of closed and open-ended 
questions was chosen to elicit additional information regarding perspectives on strategies to improve 
uptake of AIT in primary care. The survey was administered through the web based SurveyXact 
system. (SurveyXact, Aarhus, Denmark). Invitations to participate in the survey were distributed to 
European GPs via the International Primary Care Respiratory Group (IPCRG) and World Organization 
of National Colleges and Associations, Europe (WONCA); to European specialist allergy societies 
using a list supplied by EAACI; and to European allergy patient support group via the EAACI patient 
representative contacts list. Data collection took place between December 2016 and February 2017. 
Two email reminders were sent. Data were analyzed using descriptive statistics. Answers to open-
ended questions were coded using content analysis and illustrative quotes were selected (please see 
Supplement 1 in the Online repository). We recorded positive answers thereby focusing on presence 
of services, education, training, reimbursement and barriers. We pooled negative and missing 
answers as the questionnaire did not always permit us to make a clear distinction between both 
categories. We have not presented the responses from non-European sources. 
 
 
Results 
 . 
Literature search 
A total of 59 references were obtained from the combined searches. Of these, 36 were excluded as 
they provided results of clinical trials, were guidelines or cost-effectiveness analyses. A further 12 
papers were duplicates. Eleven papers were thus included; these are summarized briefly below.  
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One paper addressed care delivery in a generic fashion. It described critical factors for achieving 
good care, using efficient primary care systems to translate service delivery into high quality 
outcomes. The authors described a combination of access, continuity and comprehensiveness.
29
 A 
further paper addressed the variability in allergy care provision in primary care.
30
  Two papers focused 
on the use of specific-IgE in informing patient management as part of a strategy to improve care.
31,32 
 
Five papers studied perception, knowledge or practice of AIT across various specialist groups , 
including primary care, pediatricians and ear, nose and throat (ENT) specialists, delivering services in 
primary care across a large geographical spread.
33-37
 These papers also suggested that SCIT was 
more likely to be prescribed in specialist care and SLIT more commonly prescribed in primary care. 
 
One paper provided an historical description of allergy and how care had progressed over the last 50 
years. It highlighted that much still needed to be done to understand the predisposition to atopic 
disease and identifying the environmental cofactors involved in the 'allergic epidemic' and  
therefore targets for effective primary prevention.
38
The final paper identified common questions in 
allergy practice gathered from delegates attending a conference on allergy care.
39
  
 
In summary, this literature review described what was already known, namely that there are major 
gaps in knowledge and skills in the provision of allergy care, and that these are widespread and not 
limited to primary care. The literature review also laid bare the paucity of relevant research in primary 
care settings. The details of the search are made available in Supplement 2 in the online repository.  
 
Situational analysis 
Primary care clinician survey  
The GP survey yielded evaluable responses from 132 GPs of which 70 (52%) were from Europe (i.e. 
Greece, Ireland, Macedonia, Norway, Poland, Portugal Romania Turkey, UK).  The majority of these 
responses were from the UK and Romania (53 respondents). The paucity of responses coupled with 
poor geographical spread, led us to create a narrative summary of our findings  (Supplement 1, online 
repository.)  
 
Ten percent reported awareness of any national primary care guidelines; 13% stated that AIT was 
part of general practice training and 17% said that formal AIT training for GPs was available. 38% 
stated that GPs were aware that AIT could be administered by subcutaneous and sublingual routes. 
However, 55% felt that GPs were competent in taking an allergy history.  
 
The greatest barriers perceived for GPs working with AIT were a lack of knowledge and infrastructure 
(both 79%), concerns about reimbursement policies (68%), time pressures (67%) and suboptimal 
communication with specialists (55%). Most (67%) respondents stated they were open to 
collaboration with allergy specialists. These data strongly resonated with other published data
8,13 
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Stakeholder survey  
The stakeholder survey was sent to 173 specialist allergy societies and allergy patient support 
groups, with 50 responses (29%) covering 25 European countries. Where more than one set of data 
was received from one country, the most positive result from that country was included. The rationale 
for this was to present the best-case scenario. Table I gives the positive replies from the 25 European 
countries to a selected series of questions. From the 36 responses covering the European countries, 
18 came from allergy societies, three from patient groups and 15 were from mixed origin (GPs, 
individuals, GP societies or not stated).  
 
It would seem that AIT is available in most European countries with the exception of Bosnia and 
Herzegovina, and Malta. The most common location for administration was in specialist care (84% ), 
but in some countries administration took place in primary care (20%) or shared care (16%) settings. 
In 56% of countries did there appear to be any national policy on AIT. The absence of a national 
policy did not preclude some form of reimbursement, but countries without a national policy were less 
likely to attract any form of reimbursement. 
 
Comparing answers given to the number of question items generated, some countries clearly had a 
more comprehensive approach to allergy care (i.e. Germany, Denmark and the UK) whereas other 
countries (Malta, Portugal and Ireland appeared to have given less consideration to AIT (Table 1).  
 
With regards to barriers to delivering care as assessed by the stakeholders, accessibility (44%) and 
costs to the patient (including time missed from work and travel costs, 36%) were viewed as the 
greatest obstacles whereas safety fears (12%) were very low on the list (Table 2).  
 
 
Discussion 
The literature review and PCP and stakeholder surveys revealed knowledge and skills gaps coupled 
with non-existent or poorly formulated pathways of training and care. We found that there were more 
specialist guidelines than primary care ones and more accreditation pathways for specialists than 
PCPs. Given that specialists would be training primary care colleagues and remain a vital resource, it 
is important that pathways of care and shared care models are developed. It is to be noted that 
collaboration between PCPs and specialists was judged to a critical success factor in the Finnish 10 
Year Allergy Programme.
40
 In reality, patients will present anywhere along a pathway of care. Most 
AIT is delivered by specialists
41
 but this might alter with the availability of SLIT which is easier to 
deliver in the community. Adherence with AIT may be facilitated by the involvement of PCPs and 
pharmacists  and may result in cost savings, with specific reference to minimizing time lost from work 
by patients.
42
 Combining shared care pathways with the development of relevant competencies and 
capacities might increase accessibility to AIT. Tools such as pocket guidelines may also facilitate 
service delivery.
43
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There are three key areas which need to be addressed. The first is the development of education and 
training of PCPs. The second key area is diagnosis and stratification of patients into those who can be 
managed exclusively in primary care and those with more problematic disease who need referral to 
specialist care. The final area is service delivery and the monitoring of treatment effectiveness at the 
patient level.  
 
Education and training 
Our survey and other published data
12
 suggest that PCPs are not trained to adequately manage 
allergy patients. Allergy hardly features in most undergraduate medical curricula.
13
 There is little 
allergy training in primary care postgraduate specialist training
41
.There has though been assessment 
of training needs
44
 and identification of core competencies required
45
 which should facilitate an 
education process. We suggest that training in allergy and AIT should be included in all 
undergraduate medical curricula. Furthermore, we suggest that sufficient training in allergy and AIT is 
included in primary care postgraduate medical specialist training to allow the development of core 
competencies in the diagnosis and management of common allergic presentations. This would 
include the use and interpretation of tests used to confirm the presence of sensitization and whether 
or not this was relevant to the patients’ clinical state
46
. 
 
Dialogue between specialist and PCPs should help to improve knowledge and treatment pathways at 
a local level. The issue of reimbursement of practitioners and patients need to be recognized as these 
issues may affect the accessibility to AIT, including those related to travel and missing time from work. 
 
Diagnosis and stratification of patients 
Prior to any other intervention, a secure diagnosis needs to be made. Further, to optimize allergy 
management patients need to be stratified, probably by disease severity, into those who can be 
managed exclusively in primary care and those who need referral into specialist care. 
Characteristically, patients attending their GP or pharmacist suffer from as yet undiagnosed problems. 
A thorough history leads to a diagnosis or differential diagnosis. The his tory should guide the request 
for investigations.
47
 To firmly establish a diagnosis, a physical examination, appropriate to the 
presenting complaint and investigation(s) is likely to be required, although for some allergic disorders 
there may be no relevant physical finding.  
 
According to our survey (data not shown), many GPs across Europe have access to serum specific-
IgE testing; in contrast, very few have access to skin prick testing.
48
 Small studies confirm that such 
testing improves the ability to make a diagnosis of allergic and, importantly, of non -allergic 
diseases.
31,49 
There is a clear rationale for using specific-IgE tests in primary care.
31,50
   Further work 
needs to be undertaken around the place and utility of specific -IgE in primary care and how best to 
educate practitioners in the interpretation of results in the clinical context.
46
  This has been identified 
as a pressing research need by the IPCRG.
51
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Service delivery and monitoring 
Developing vertically integrated care pathways might be one way of developing a process for service 
delivery.
52
 Such a pathway could include community pharmacists to aid in identification of patients ; 
they may also be able to play a role in promoting adherence. The patient journey often commences 
with the community pharmacist, providing a rationale for including them in any proposed care.
53
 A 
further option to be considered, particularly where specialists are scarce, is the development of a 
network of GPs with specialist interests (GPwSIs) whose remit would include service provision and 
local educational initiatives working in close collaboration with specialist mentors
54,55
This would also 
present an opportunity to develop a network of care to establish clear communication and shared 
decision making.  
 
Strengths and limitations of the surveys 
An exploratory analysis is presented, the first of its kind. The study focuses on the views of primary 
care clinicians and relevant stakeholders concerning allergy care and AIT and on barriers in this field. 
The main limitation of this study is the low response rate, particularly in the GP survey. It was difficult 
to identify appropriate respondents for each country. A substantial number of stakeholder responses 
came neither from patient groups nor from allergy societies, thus responses may not be completely 
representative of the situation in specific countries although together they provide a reasonable 
description of the reality across Europe.  Finally, although the surveys give a good impression of 
available services and barriers for GPs in Europe, pooling negative and missing responses and 
classifying the latter as negative, limits the accuracy of the outcome.  
 
Looking ahead 
Based on our findings, we have made some recommendations (see Table III). Although our findings 
seem somewhat discouraging, there is room for optimism. Clinical trials in AIT have been successfully 
carried out in primary care, demonstrating proof of concept.
56,57 
It is of further interest that in a real-li fe 
study of AIT adherence carried out in the Netherlands, that adherence and persistence was higher 
amongst patients of GPs than those of allergists or other specialists
58
The development of pathways of 
care should facilitate the delivery of high quality effective services  and improve patient selection. 
These will vary from health system to health system depending on existing configuration, but are likely 
to have similar themes. Such pathways would aim to establish a register of those who had received 
AIT to facilitate identification of type and severity of side -effects as well as permit the assessment of 
effectiveness of AIT in different patient types which would ultimately aid in patient selection. This 
would be facilitated by the development of a template which would permit uniformity of coding and 
clinical parameters entered. This should incorporate a mechanism whereby primary care can report 
safety issues and adverse effects via a web based registry system. In addition, network of care with 
specialists and primary care professionals needs to be developed to establish clear communication 
and shared decision making. If, as is happening in some countries, PCPs commence immunotherapy 
without specialist referral, they should ensure that the products used have proven safety and efficacy . 
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Conclusions 
We have undertaken this work to explore how the EAACI Guidelines on Allergen Immunotherapy for 
the prevention and management of allergic conditions might be implemented in primary care. The 
findings from this mixed-methods evaluation strongly suggest that European primary care providers 
are sub-optimally positioned to identify and manage those who are most likely to benefit from AIT. We 
have identified a number of important barriers – including educational and training, infrastructural and 
financial – that need to be overcome in order to scale-up AIT delivery across Europe. In order to 
encourage the successful adoption of AIT as a mainstream therapy, there needs to be wide spread 
publicity concerning its effectiveness. Health care provision has great heterogeneity across Europe: 
the generic recommendations made in this paper will therefore need to be interpreted and tailored in 
line with local health care policies and priorities. Commissioners of health services and politicians 
need to be made aware of potential benefits and ultimately cost savings  in line with the triple aim of 
health care: better patient experience, improving the health of populations and reducing the cost of 
health care.  
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Table 1 Survey. Current situation 
X represent a positive response.  %: percentage of positive responses. Abbreviations: AL Albania, BA Bosnia and Herzegovina, BG Bulgaria,  CH Switzerland 
, CY Cyprus , CZ Czech Republic,  DE Germany, DK Denmark, EE Estonia, ES Spain, FI Finland, HR Croatia, IE Ireland , IT Italy, LV Latvia , MT Malta, NL 
Netherlands, PL Poland, PO Portugal, RO Romania , RS Serbia , SL Slovenia , SE Sweden ,  TR Turkey, UK United Kingdom   
  
AL BA BG CH CY CZ DE DK EE ES FI HR IE IT LV MT NL PL PO RO RS SE SL TR UK % 
Availability of Immunotherapy x x x x x x x x x x x x x x x x x x x x x x x 92
National Policy x x x x x x x x x x x x x x 56
Primary Care x x x x x x x 28
Specialist Care x x x x x x x x x x x 44
Is there an accreditation pathway for Specialists x x x x x x x x x x 40
Is there an accreditation pathway for Primary Care x x x x 16
Shared Care x x x x x x x x x x x 44
Referral Criteria x x x x x x x x x x x x 48
Follow up monitoring x x x x x x x x x x x x 48
Agreed care between professionals x x x x x x x x 32
Training Pathways x x x x x x x x x x 40
Specialist x x x x x x x x x x x x x x x x x x x x x 84
Primary Care x x x x x 20
Shared Care x x x x 16
Specialist x x x x x x x x x x x x x x x x x x x x x 84
Patient x x x x x x x 28
Primary Care x x x 12
Any x x x x x x x x x x x x x x 56
Full reimbursement x x x x x x x x 32
Partial reimbursement x x x x x x 24
Is there reimbursement for administration of AIT? x x x x x x x x x x x x 48
Agreed Pathway
The location of administration of SCIT
Who makes the decision to discontinue treatment?
National Guidelines
Is there reimbursement of the product?
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Table 2 Survey. Barriers 
 
 
 
Key Recomendations Barriers Facilitators Key References 
1. Teaching in allergy and AIT 
should be included in all 
undergraduate medical 
curricula.  
 Low priority on educational 
agenda. 
 Inadequate skills and knowledge in 
the medical work force. 
 Inadequate representation of 
Allergy in general Undergraduate 
or Postgraduate curricula.  
 Allergy campaigns to raise awareness to 
governments and patients. 
 Workforce remodeling with collaborative 
relationships with specialists. 
 Clinical system wide leadership with 
investment in education and training. 
Potter,2009
59
. 
Campbell 2015
38
 
Shehata 2006
13
 
2. There should be sufficient 
training in allergy and AIT 
included in primary care 
postgraduate medical specialist 
training to allow the 
development of core 
competencies in the diagnosis 
and management of common 
allergic presentations.  
 Low priority on political agenda 
with lack of treatment prioritization. 
 Inadequate health economics data 
and population based outcomes.  
 Inadequate representation of 
Allergy in general Undergraduate 
or Postgraduate curricula.  
 Workforce remodeling with collaborative 
relationships with specialists. 
 Clinical system wide leadership with 
investment in education and training. 
Campbell 2015,
38
 
Tan 2014,
39
 
Eigenmann 2013
60
 
Wallengren 2011
45
 
AL BA BG CH CY CZ DE DK EE ES FI HR IE IT LV MT NL PL PO RO RS SE SL TR UK  % 
Fees for time x x x x 16
Reimbursement barriers to patients travel costs x x x x 16
Time off work for patients x x x x x x 24
Accessibility x x x x x x x x x x x 44
Beliefs about efficacy x x x x x x x 28
Beliefs about safety x x x 12
Costs to patients travel time and time off work etc. x x x x x x x x x 36
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3. Primary care workers should 
have access to specific-IgE 
testing and, if required, have 
assistance in interpretation of 
results. 
 Inadequate skills and knowledge in 
the medical work force. 
 Poor understanding of diagnostic 
tests in primary care used in the 
assessment and diagnosis of 
allergy. 
 Lack of clear care pathways and 
referral criteria.  
 Heterogeneous reimbursement 
policies for investigations and their 
administration.  
 Clinical system wide leadership 
with investment in education and 
training. 
 System wide health care delivery mirroring 
patient journey from pharmacists through to 
specialists. 
 Harmonization of reimbursement policies. 
 
Pelone 2013
29
. 
Hansen 2010
30
, 
Dranitsaris 2014.
42
 
Ellis 2012.
44
 
Bousquet 2015
61
 
4. There is a need to develop and 
implement vertically integrated 
care pathways to improve 
delivery of allergy care and AIT. 
This could include clinical 
decision support systems. It 
may involve the development of 
intermediate level GPs with a 
specialist interest in allergy. 
 Lack of clear care pathways and 
referral criteria.  
 Inadequate health economics data 
and population based outcomes.  
 Heterogeneous reimbursement 
policies for products and their 
administration.  
 Allergy campaign
62
s to raise awareness to 
governments and patients. 
 System wide health care delivery mirroring 
patient journey from pharmacists through to 
specialists. 
 Practice nurses involved in delivery of care, 
under supervision, allowing flexibility of 
approach delivering care closer to home.  
Diwakar 2017.
14
 
Smith 2009.
47
 
Fromer 2014.
50
, 
Bousquet 2016.
63
 
Yao 2015 , 
Flokstra - de Blok 
2017.
64
 
Ryan 2005
54
 
 
5. Develop specific 
recommendations to aid 
identification, stratification and 
referral criteria to enable 
effective referrals from primary 
or specialist care.  
 Low priority on political agenda 
with lack of treatment prioritization. 
 Inadequate skills and knowledge in 
the medical work force.   
 Lack of clear care pathways and 
referral criteria.  
 Workforce remodeling with collaborative 
relationships with specialists. 
Haahtela 2008
40
 
Ryan 2017
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